Equities

Valbiotis SA

Valbiotis SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)1.33
  • Today's Change-0.028 / -2.07%
  • Shares traded22.37k
  • 1 Year change-74.69%
  • Beta0.0288
Data delayed at least 15 minutes, as of Sep 20 2024 16:29 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Valbiotis SA is a France-based company engaged in the biotechnology industry. The Company specializes in developing nutrition solutions designed to prevent cardiometabolic diseases and provide nutritional support for patients. It seeks to develop solutions designed to prevent type 2 diabetes, NASH, (non-alcoholic steatohepatitis) and obesity and to offer nutritional support. The Company prevents disease by developing products that reduce the risk factors of irreversible chronic diseases. It provides patient support through new-generation medical nutrition solutions containing patented substances with clinically proven effects. Its products are plant-based and undergo strict scientific and clinical tests in collaboration with academic research centers.

  • Revenue in EUR (TTM)4.73m
  • Net income in EUR-7.37m
  • Incorporated2014
  • Employees52.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Theranexus SA0.00-6.83m4.64m19.00--2.09-----1.09-1.090.000.28630.00----0.00-70.79-42.66-82.29-47.97-----------1,058.680.6212-------3.97---33.23--
Acticor Biotech SA0.00-18.64m4.88m28.00---------1.55-1.550.00-0.40280.00----0.00-164.53---568.29-------------19.8510.47-------17.40------
Phaxiam Therapeutics SA1.33m-23.49m16.47m51.00--0.4234--12.42-5.14-5.140.29013.900.0273--14.8226,000.00-48.37-50.69-66.94-66.25-----1,771.42-1,009.09---70.210.3412---80.05-21.50-10,201.75---56.68--
Plant Advanced Technologies PAT SA1.68m79.16k16.71m27.00207.041.9428.819.930.07250.07251.547.730.1118-0.41231.6062,278.520.5262-3.530.6534-4.39128.03134.214.71-33.160.4183-15.320.3402--8.568.05119.67-38.00----
Oncodesign Precision Medicine Opm SA1.07m-8.09m18.37m22.00--4.55--17.14-0.4863-0.48630.06450.22190.0613--1.3948,735.00-46.23---63.87--130.48---754.61------0.7052---86.57---3,399.73------
Predilife SA317.79k-4.22m18.61m19.00------58.57-1.14-1.140.0858-1.060.0695--2.0517,030.55-92.43-89.36-129.39-123.8197.2583.94-1,329.21-1,901.22---6.232.20--10.1179.85-15.58---18.51--
Nfl Biosciences SAS0.00-3.75m19.70m3.00--10.68-----0.4674-0.46740.000.19010.00----0.00-117.67-83.27-292.70-122.37------------0.0388-------53.28------
Valbiotis SA4.73m-7.37m20.94m52.00--1.07--4.43-0.5904-0.59040.37981.240.15643.3617.8391,019.23-24.35-32.92-33.77-46.3648.7653.15-155.67-418.873.38-38.190.2598--502.93126.7340.16---21.71--
Poxel SA1.55m-44.24m29.95m30.00------19.37-1.44-1.440.0507-1.220.0597--5.4230,920.00-170.71-31.97-432.50-55.940.1294---2,861.58-101.47---4.0811.28---94.97-33.77-32.13---8.49--
Fermentalg SA8.04m-14.14m32.74m62.00--0.4976--4.07-0.2836-0.28360.15640.76370.13951.344.82129,629.00-22.80-21.94-25.70-24.7114.0414.73-163.46-248.953.42-53.730.2639---46.9475.18-43.29---10.93--
genOway SA20.05m1.57m36.26m133.0021.952.089.041.810.17820.17822.281.880.6190.7733.10150,724.704.840.21666.640.304895.8294.827.820.41771.9528.110.3047--17.5513.16101.5522.35----
Gensight Biologics SA1.27m-26.22m40.82m16.00------32.22-0.5427-0.54270.0269-0.47260.0723--2,534.0079,187.50-149.52-79.44---144.54-----2,069.53-1,036.27---------50.93--5.09---58.28--
Data as of Sep 20 2024. Currency figures normalised to Valbiotis SA's reporting currency: Euro EUR

Institutional shareholders

11.11%Per cent of shares held by top holders
HolderShares% Held
OFI Invest Asset Management SAas of 29 Aug 2024607.52k3.85%
Amiral Gestion SAas of 30 Jun 2023371.36k2.35%
Talence Gestion SASas of 30 Aug 2024256.39k1.62%
UBS LA MAISON de Gestionas of 30 Dec 2022150.00k0.95%
Friedland Gestion SASas of 31 May 2024114.78k0.73%
Hermitage Gestion Priv�e SAas of 29 Dec 202380.00k0.51%
Financi�re Arbevel SAas of 30 Dec 202279.99k0.51%
Pure Capital SAas of 31 Dec 202344.84k0.28%
MW Gestion SAas of 31 Dec 202333.63k0.21%
Mandarine Gestion SAas of 30 Jun 202316.24k0.10%
More ▼
Data from 30 Jun 2023 - 01 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.